Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ginsenoside 20(S)-Rh2** is a dammarane-type triterpenoid saponin and a bioactive component of Panax ginseng and Panax notoginseng. It is present in very low amounts in red ginseng and is mainly recognized for its potent antitumor properties, including apoptosis induction, inhibition of cancer cell proliferation, metastasis, and modulation of tumor cell energy metabolism. Its proposed mechanisms include direct binding and inhibition of Annexin A2 (reducing NF-κB signaling and survival gene expression), inhibition of PI3K/Akt/mTOR and STAT3/c-Myc pathways, enhancement of caspase activation, and modulation of death receptor 5 (DR5) activity. The compound sensitizes cancer cells to TRAIL-induced apoptosis and may enhance efficacy of anticancer agents. Ginsenoside 20(S)-Rh2 also possesses hepatoprotective, cardioprotective, bone density conservation, and antibacterial properties, including the capacity to increase intracellular antibiotic accumulation via inhibition of P-gp and BCRP efflux transporters[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginsenoside 20(S)-Rh2.